MedElevator
Войти в исследования Khirurgiia · 2026
[Remaxol in perioperative infusion therapy for patients with calculous obstructive jaundice: a multiple-center observational study].
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеАннотация на английскомНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Demko A E, Tumaev I E, Lopukhov E S, Khazova E V, Safonov A S, Sardinov R T, Kalachev S V
Аннотация
OBJECTIVE: To analyze the effect of Remaxol (Inosine + Meglumine + Methionine + Nicotinamide + Succinic Acid) in perioperative infusion therapy (PITh) on bilirubinemia in patients with cholelithiasis (CL) complicated by obstructive jaundice (OJ).
MATERIAL AND METHODS: A multiple-center observational study included 283 patients with CL complicated by OJ. All patients underwent endoscopic papillosphincterotomy (EPST) with / without subsequent laparoscopic cholecystectomy (LC). Primary assessment of PITh efficacy was performed on days 6-7 after EPST. Bilirubinemia was compared with the day before EPST. A positive response to therapy was defined as normalization of total blood bilirubin or its reduction by 70%.
RESULTS: Factors influencing the efficacy of PITh in patients with OJ were identified. Positive response rate was 100% in patients receiving PITh with Remaxol proportion exceeding 80% (p=0.005). In case of Remaxol proportion >50%, positive response rate was 96.88% (p=0.001). In the group with Remaxol proportion <50%, positive response rate was 68% compared to the group with proportion >50% (p<0.001). Each 10% increase in proportion of Remaxol increased the probability of positive response to treatment by 13% (p=0.017).
CONCLUSION: Inclusion of Remaxol (Inosine + Meglumine + Methionine + Nicotinamide + Succinic Acid) in perioperative PITh for patients with OJ may have a positive effect on total blood bilirubin and increase the likelihood of normalization of this parameter or significant (by ≥70%) reduction in 6-7 days after successful EPST.
MATERIAL AND METHODS: A multiple-center observational study included 283 patients with CL complicated by OJ. All patients underwent endoscopic papillosphincterotomy (EPST) with / without subsequent laparoscopic cholecystectomy (LC). Primary assessment of PITh efficacy was performed on days 6-7 after EPST. Bilirubinemia was compared with the day before EPST. A positive response to therapy was defined as normalization of total blood bilirubin or its reduction by 70%.
RESULTS: Factors influencing the efficacy of PITh in patients with OJ were identified. Positive response rate was 100% in patients receiving PITh with Remaxol proportion exceeding 80% (p=0.005). In case of Remaxol proportion >50%, positive response rate was 96.88% (p=0.001). In the group with Remaxol proportion <50%, positive response rate was 68% compared to the group with proportion >50% (p<0.001). Each 10% increase in proportion of Remaxol increased the probability of positive response to treatment by 13% (p=0.017).
CONCLUSION: Inclusion of Remaxol (Inosine + Meglumine + Methionine + Nicotinamide + Succinic Acid) in perioperative PITh for patients with OJ may have a positive effect on total blood bilirubin and increase the likelihood of normalization of this parameter or significant (by ≥70%) reduction in 6-7 days after successful EPST.